Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount.
View Article and Find Full Text PDFTrimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount.
View Article and Find Full Text PDFProbl Endokrinol (Mosk)
December 2007
То study a role of hemodynamic and humoral factors in the development of arterial hypertension and myocardial hypertrophy, 20 and 21 patients with acromegalia were examined before and in the late periods after radical surgical treatment, respectively, for growth hormone-producing pituitary adenoma. The patients underwent blood pressure and central hemodynamic measurements, echocardiography, and some hormones testing at rest and after antiorthostatic tests and exercises. In patients with acromegalia, arterial hypertension occurring in the late postoperative periods was ascertained to be associated with higher vascular resistance, exhausted depressor prostaglandin system, impaired aldosterone and Cortisol reactivity, and insulin hypertension.
View Article and Find Full Text PDF